Evidence of Lysosomal β-Hexosaminidase Enzymatic Activity Associated with Extracellular Vesicles: Potential Applications for the Correction of Sandhoff Disease
Source abstract
Abstract
Extracellular vesicles (EVs) can be isolated from biological fluids and cell culture medium. Their nanometric dimension, relative stability, and biocompatibility have raised considerable interest for their therapeutic use as delivery vehicles of macromolecules, namely nucleic acids and proteins. Deficiency in lysosomal enzymes and associated proteins is at the basis of a group of genetic diseases known as lysosomal storage disorders (LSDs), characterized by the accumulation of undigested substrates into lysosomes. Among them, GM2 gangliosidoses are due to a deficiency in the activity of lysosomal enzyme β-hexosaminidase, leading to the accumulation of the GM2 ganglioside and severe neurological symptoms. Current therapeutic approaches, including enzyme replacement therapy (ERT), have proven unable to significantly treat these conditions. Here, we provide evidence that the lysosomal β-hexosaminidase enzyme is associated with EVs released by HEK cells and that the EV-associated activity can be increased by overexpressing the α-subunit of β-hexosaminidase. The delivery of EVs to β-hexosaminidase-deficient fibroblasts results in a partial cross-correction of the enzymatic defect. Overall findings indicate that EVs could be a source of β-hexosaminidase that is potentially exploitable for developing therapeutic approaches for currently untreatable LSDs.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Extracellular vesicles in disease · Mosquito-borne diseases and control · Lysosomal Storage Disorders Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry, Biology and Biotechnology, University of Perugia, 06100 Perugia, Italy
Centro di Eccellenza sui Materiali Innovativi Nanostrutturati (CEMIN), University of Perugia, 06123 Perugia, Italy
Istituto Superiore di Sanità (ISS), 00161 Rome, Italy
Funding
The European Union-NextGenerationEU under the Italian Ministry of University and Research (MUR) National Innovation Ecosystem
References (37)
Show source-provided references
1. Kalra, H., Drummen, G.P., and Mathivanan, S. (2016). Focus on Extracellular Vesicles: Introducing the Next Small Big Thing. Int. J. Mol. Sci., 17.10.3390/ijms17020170 ↗
2. Biological properties of extracellular vesicles and their physiological functions10.3402/jev.v4.27066 ↗
3. Communication by Extracellular Vesicles: Where We Are and Where We Need to Go10.1016/j.cell.2016.01.043 ↗
4. Extracellular vesicles and nanoparticles: Emerging complexities10.1016/j.tcb.2023.01.002 ↗
5. Extracellular vesicles: A new communication paradigm?10.1038/s41580-019-0158-7 ↗
6. Extracellular vesicles versus synthetic nanoparticles for drug delivery10.1038/s41578-020-00277-6 ↗
7. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes10.1038/nbt.1807 ↗
8. Exosome- and extracellular vesicle-based approaches for the treatment of lysosomal storage disorders10.1016/j.addr.2022.114465 ↗
9. Extracellular vesicle-based therapeutics: Natural versus engineered targeting and trafficking10.1038/s12276-019-0223-5 ↗
10. Β-hexosaminidase over-expression affects lysosomal glycohydrolases expression and glycosphingolipid metabolism in mammalian cells10.1007/s11010-011-1163-0 ↗
11. Physiological substrates for human lysosomal beta-hexosaminidase S10.1074/jbc.M105457200 ↗
12. Crystal structure of human beta-hexosaminidase B: Understanding the molecular basis of Sandhoff and Tay-Sachs disease10.1016/S0022-2836(03)00216-X ↗
13. Biochemical consequences of mutations causing the GM2 gangliosidoses10.1016/S0925-4439(99)00074-5 ↗
14. Leal, A.F., Benincore-Flórez, E., Solano-Galarza, D., Garzón Jaramillo, R.G., Echeverri-Peña, O.Y., Suarez, D.A., Alméciga-Díaz, C.J., and Espejo-Mojica, A.J. (2020). GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies. Int. J. Mol. Sci., 21.10.20944/preprints202007.0137.v2 ↗
15. Genetics and Therapies for GM2 Gangliosidosis10.2174/1566523218666180404162622 ↗
16. New strategies for the treatment of lysosomal storage diseases (review)10.3892/ijmm.2012.1187 ↗
17. Fernández-Pereira, C., San Millán-Tejado, B., Gallardo-Gómez, M., Pérez-Márquez, T., Alves-Villar, M., Melcón-Crespo, C., Fernández-Martín, J., and Ortolano, S. (2021). Therapeutic Approaches in Lysosomal Storage Diseases. Biomolecules, 11.10.3390/biom11121775 ↗
18. Substrate Reduction Therapy for Sandhoff Disease through Inhibition of Glucosylceramide Synthase Activity10.1016/j.ymthe.2019.05.018 ↗
19. An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants)10.1016/j.ymgme.2010.09.004 ↗
20. The GM2 gangliosidoses: Unlocking the mysteries of pathogenesis and treatment10.1016/j.neulet.2021.136195 ↗
21. Therapeutic Strategies For Tay-Sachs Disease10.3389/fphar.2022.906647 ↗
22. Edelmann, M.J., and Maegawa, G.H.B. (2020). CNS-Targeting Therapies for Lysosomal Storage Diseases: Current Advances and Challenges. Front. Mol. Biosci., 7.10.3389/fmolb.2020.559804 ↗
23. Calzoni, E., Cesaretti, A., Montegiove, N., Di Michele, A., Pellegrino, R.M., and Emiliani, C. (2022). HexA-Enzyme Coated Polymer Nanoparticles for the Development of a Drug-Delivery System in the Treatment of Sandhoff Lysosomal Storage Disease. J. Funct. Biomater., 13.10.3390/jfb13020037 ↗
24. Calzoni, E., Cesaretti, A., Montegiove, N., Di Michele, A., and Emiliani, C. (2021). Enhanced Stability of Long-Living Immobilized Recombinant β-d-N-Acetyl-Hexosaminidase A on Polylactic Acid (PLA) Films for Potential Biomedical Applications. J. Funct. Biomater., 12.10.3390/jfb12020032 ↗
25. Koelmel, J.P., Li, X., Stow, S.M., Sartain, M.J., Murali, A., Kemperman, R., Tsugawa, H., Takahashi, M., Vasiliou, V., and Bowden, J.A. (2020). Lipid Annotator: Towards Accurate Annotation in Non-Targeted Liquid Chromatography High-Resolution Tandem Mass Spectrometry (LC-HRMS/MS) Lipidomics Using a Rapid and User-Friendly Software. Metabolites, 10.10.3390/metabo10030101 ↗
26. LC/MS lipid profiling from human serum: A new method for global lipid extraction10.1007/s00216-014-8255-0 ↗
27. Sagini, K., Buratta, S., Delo, F., Pellegrino, R.M., Giovagnoli, S., Urbanelli, L., and Emiliani, C. (2021). Drug-Induced Lysosomal Impairment Is Associated with the Release of Extracellular Vesicles Carrying Autophagy Markers. Int. J. Mol. Sci., 22.10.3390/ijms222312922 ↗
28. Saint-Pol, J., Gosselet, F., Duban-Deweer, S., Pottiez, G., and Karamanos, Y. (2020). Targeting and crossing the blood-brain barrier with extracellular vesicles. Cells, 9.10.3390/cells9040851 ↗
29. Ridder, K., Keller, S., Dams, M., Rupp, A.K., Schlaudraff, J., Del Turco, D., Starmann, J., Macas, J., Karpova, D., and Devraj, K. (2014). Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation. PLoS Biol., 12.10.1371/journal.pbio.1001874 ↗
30. Identification of plasma membrane associated mature beta-hexosaminidase A, active towards GM2 ganglioside, in human fibroblasts10.1016/j.febslet.2005.08.081 ↗
31. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines10.1080/20013078.2018.1535750 ↗
32. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches10.1002/jev2.12404 ↗
33. Lysosomal N-acetyltransferase interacts with ALIX and is detected in extracellular vesicles10.1016/j.bbamcr.2018.07.001 ↗
34. Umbilical mesenchymal stem cell-derived extracellular vesicles as enzyme delivery vehicle to treat Morquio A fibroblasts10.1186/s13287-021-02355-0 ↗
35. Iglesias, D.M., El-Kares, R., Taranta, A., Bellomo, F., Emma, F., Besouw, M., Levtchenko, E., Toelen, J., van den Heuvel, L., and Chu, L. (2012). Stem cell microvesicles transfer cystinosin to human cystinotic cells and reduce cystine accumulation in vitro. PLoS ONE, 7.10.1371/journal.pone.0042840 ↗
36. Targeted delivery of lysosomal enzymes to the endocytic compartment in human cells using engineered extracellular vesicles10.1038/s41598-019-53844-5 ↗
37. Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders10.1002/jev2.12058 ↗